All In Biotech

Drug Trial Radar · NCT06365216

ALS Phase II Study of NX210c

A Double-blind, Randomized, Placebo-controlled, Multicentric, Phase II Study in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Multiple Intravenous Infusions of NX210c

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

83

Actual

Start

Oct 25, 2024

Primary completion

Dec 29, 2025

Study completion Sep 8, 2026

Sponsor

Lead sponsor
Axoltis PharmaIndustry
Sponsor type
Industry
Collaborators
ACT4ALS network
First posted
Apr 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will investigate the efficacy, safety, tolerability and pharmacokinetics (PK) of multiple intravenous infusions of NX210c, at two dose levels, in patients with Amyotrophic lateral sclerosis (ALS).

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • NX210cDrug

    3 times a week, for 4 weeks

  • PlaceboDrug

    3 times a week, for 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The effect of NX210c on blood neurofilament light chain (NfL) or on a blood and cerebrospinal fluid (CSF) biomarker of BBB integrity.Time frame: From predose to 6-week follow-up

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Centre Hospitalier Universitaire d'Angers

    Angers, France

  • Centre Hospitalier Universitaire De Bordeaux

    Bordeaux, France

  • CHU de Lyon HCL

    Bron, France

  • Centre Hospitalier Universitaire de Clermont-Ferrand - Hôpital Gabriel Montpied

    Clermont-Ferrand, France

  • Centre Hospitalier Universitaire de Lille

    Lille, France

  • Centre Hospitalier Et Universitaire de Limoges

    Limoges, France

  • Centre Hospitalier Universitaire de Montpellier

    Montpellier, France

  • Centre Hospitalier Universitaire de Nantes - Hôpital Nord Laennec

    Nantes, France

  • Centre Hospitalier Universitaire de Nice

    Nice, France

  • Hôpital de la Pitié Salpêtrière

    Paris, France

  • Centre Hospitalier Universitaire de Rennes

    Rennes, France

  • Centre Hospitalier Regional Universitaire de Tours

    Tours, France

  • Centre Hospitalier Regional Et Universitaire De Brest

    Brest, France, France

  • Centre Hospitalier Universitaire De Caen Normandie

    Caen, France, France

  • Hôpital La Timone - APHM

    Marseille, France, France

  • CHRU De Nancy

    Nancy, France, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.